Products & Pipeline

OSI’s portfolio of products and product candidates are designed to improve upon the existing treatment options for patients suffering from cancer, diabetes and obesity.

A Rich Pipeline of Innovative Products and Product Candidates

A key to our long-term success resides in our ability to continue to fund our innovative and differentiated pipeline, both to enhance the Tarceva franchise and seed high-quality research programs in oncology, diabetes and obesity.

ProductDescriptionStatus
TARCEVA®(erlotinib)*HER 1/EGFR Inhibitor 
2nd/3rd Line NSCLC
Marketed
Pancreatic Cancer
Marketed
Erlotinib tabletsHER 1/EGFR Inhibitor 
1st Line Maintenance NSCLC
Phase III
Adjuvant NSCLC
Phase III
Ovarian and Colorectal Cancer
Phase III
Other Indications
Phase II
OSI-906IGF-1R Inhibitor 
Adrenocortical Carcinoma
Phase III
Ovarian Cancer
Phase I/II
OSI-027TORC1/TORC2 InhibitorPhase I
OSI-930c-kit/VEGFR-2Phase I
 
* OSI markets Tarceva through partnerships with Genentech in the United States and with Roche throughout the rest of the world

Access more information on our oncology programs

ProductDescriptionStatus
PSN602S1RUP InhibitorPhase I
PSN821G-protein Coupled Receptor (GPCR)Phase I
PSN010**Glucokinase Activator (GKA)Phase I
 
** OSI entered into a licensing agreement granting Eli Lilly exclusive rights to PSN010

Access more information on our diabetes and obesity programs

OSI Oncology

OSI Oncology is committed to taking cutting-edge MTTs from bench to bedside through rigorous research and aggressive development. This is not an aspiration, it is a reality for OSI Oncology as demonstrated by our commitment to personalized medicine and the development of our lead molecular targeted therapy and Tarceva.

Oncology Pipeline

OSI-906 and OSI-027 are two potential first-in-class product candidates discovered and wholly owned by OSI. Both are currently in Phase I clinical trials.

OSI Oncology

(OSI) Prosidion is developing safer, more effective, innovative products for the treatment of metabolic diseases, particularly type 2 diabetes and obesity. The product pipeline currently supports several active programs.

Learn more